Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Programmable implants--from pulsatile to controlled release.

C Guse1, S Koennings, T Blunk

  • 1Department of Pharmaceutical Technology, University of Regensburg, Universitätsstrasse 31, D-93040 Regensburg, Germany.

International Journal of Pharmaceutics
|March 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracochlear PLGA implants for simultaneous controlled release of multiple drugs.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Release mechanisms of PLGA-based drug delivery systems: A review.

International journal of pharmaceutics: X·2025
Same author

Release mechanisms of PLGA microparticles prepared using a microfluidics device or a beaker.

International journal of pharmaceutics: X·2025
Same author

It is not waste if it is therapy: cellular, secretory and functional properties of reamer-irrigator-aspirator (RIA)-derived autologous bone grafts.

Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology·2025
Same author

EVA implants for controlled drug delivery to the inner ear.

International journal of pharmaceutics: X·2024
Same author

In-situ forming PLGA implants: Towards less toxic solvents.

International journal of pharmaceutics·2024
Same journal

Artificial intelligence and CRISPR-based approaches for targeted delivery of bacteriophages.

International journal of pharmaceutics·2026
Same journal

A "three-in-one" nose-to-brain delivery strategy: intranasal vancomycin spray achieves simultaneous clearance of pneumococcal colonization, bacteremia, and meningitis.

International journal of pharmaceutics·2026
Same journal

10-Hydroxy-2-decenoic acid /matrine deep eutectic solvent encapsulated in hyalurosomes for enhanced transdermal delivery and antioxidant efficacy.

International journal of pharmaceutics·2026
Same journal

Dual-trigger hyaluronic acid nanoprodrug incorporating a 2-nitrobenzenesulfonyl linker for CD44-targeted and glutathione-responsive drug delivery.

International journal of pharmaceutics·2026
Same journal

Polymeric mixed micellar nanogel enhances dermal delivery and therapeutic efficacy of tofacitinib citrate.

International journal of pharmaceutics·2026
Same journal

Localized gold nanoparticles-mediated photothermal therapy for head and neck cancer: in vivo proof-of-concept.

International journal of pharmaceutics·2026
See all related articles

Researchers developed programmable implants with tunable drug release profiles. These implants offer reproducible delayed onset and extended controlled release, utilizing biodegradable polymers and triglyceride cores for predictable therapeutic delivery.

Area of Science:

  • Biomaterials Science
  • Drug Delivery Systems
  • Polymer Chemistry

Background:

  • Controlled drug release is crucial for effective long-term therapies.
  • Existing implants often lack precise control over release initiation and duration.
  • Biodegradable polymers offer potential for programmable drug delivery systems.

Purpose of the Study:

  • To engineer programmable implants with reproducible delayed drug release.
  • To achieve extended controlled release periods lasting several weeks.
  • To investigate the impact of mantle and core materials on release kinetics.

Main Methods:

  • Fabrication of implants with a drug-loaded core and a bulk-eroding polymer mantle (poly(D,L lactic-co-glycolic acid) or poly(D,L lactic acid)).
  • Optimization of manufacturing for three mantle materials to achieve varying delay times (7–83 days).

Related Experiment Videos

  • Evaluation of triglycerides (C12–C18 fatty acid chains) as core materials for controlled release (2–16 weeks).

    • Main Results:

    • Successful development of programmable implants with tunable delayed release onset.
    • Demonstrated control over release duration, ranging from 2 to 16 weeks.
    • Validated the use of biodegradable polymers and triglyceride cores for predictable drug release profiles.

    Conclusions:

    • Programmable implants with reproducible delayed and controlled release were successfully developed.
    • The choice of mantle and core materials significantly influences release kinetics.
    • A convolution/deconvolution model can predict the drug release profiles of these novel implants.